Byondis B.V., headquartered in the Netherlands, is a pioneering biopharmaceutical company specialising in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2013, Byondis has rapidly established itself as a key player in the oncology sector, focusing on targeted therapies that enhance the efficacy and safety of cancer treatments. With a strong presence in Europe and expanding operations in the United States, Byondis is committed to advancing its proprietary technologies, including its unique linker and payload systems. The company’s flagship product, a novel ADC, exemplifies its dedication to improving patient outcomes through precision medicine. Byondis has garnered recognition for its scientific advancements and strategic partnerships, positioning itself as a leader in the biopharmaceutical landscape.
We don't have data for Byondis B.V., but we can show you information about their parent organization instead.
View parent company